Results 211 to 220 of about 406,045 (339)

Immune Checkpoint Inhibitor-Induced Myocarditis: A Late Presentation. [PDF]

Ochsner J
Koos A, Shariati F, Anand S.
europepmc   +1 more source

Hypofractionated Radiotherapy Induces ISG15+MHC‐I+ Neutrophils to Augment Anti‐Tumor Immunity and Prime Immune Checkpoint Blockade Responses in Rectal Cancer

Advanced Science, EarlyView.
ABSTRACT Our previous clinical trials had demonstrated that neoadjuvant hypofractionated radiotherapy (HFRT) combined with immunotherapy yields promising clinical outcomes in locally advanced rectal cancer (LARC). However, this combined modality benefits only a subset of patients, highlighting the need to uncover the mechanisms underlying how ...
Lichao Liu, Haihong Wang, Mingjie Li, Qian Xu, Linlin Zheng, Chaoqun Han, Zhenwei Zou, Jinghua Ren, Xiaorong Dong, Peng Zhang, Kaixiong Tao, Zhenyu Lin, Tao Zhang   +12 more
wiley   +1 more source

Immune Checkpoint Inhibitor-Induced Endocrine Dysfunction: Early Detection of Symptoms and Timely Intervention. [PDF]

Clin Case Rep
Obaed NG, Fofana K, Matarneh A, Sardar S, Trivedi N, Ghahramani N.   +5 more
europepmc   +1 more source

DMAP1 Deficiency Suppresses Lung Cancer Progression by Destabilizing Replication Fork and Activating IFN Signaling‐Mediated Anti‐tumor Immunity

Advanced Science, EarlyView.
Lung cancer remains the leading cause of cancer‐related death. We investigated the role of the epigenetic regulator DMAP1 in NSCLC and found that its loss induces replication stress and DNA damage. This in turn activates type I IFN signaling via the cGAS–STING pathway and transcriptional ISG de‐repression, enhancing anti‐tumor immune responses ...
Kan Huang, Xi Dai, Shuaihu Li, Yingxue Chen, Yaxin Yu, Lin Wang, Kun Liu, Shuhan Lyu, Chongyang Li, Yihua Sun, Fei Li   +10 more
wiley   +1 more source

Efficacy of Immune Checkpoint Inhibitors and Oncoviruses in Solid Tumors. [PDF]

Clin Cancer Res
Mechahougui H, Royston L, Vieira Gomes C, Kaiser L, Koessler T, Olivier T, Mach N, Labidi-Galy SI, Parikh K, Addeo A.   +9 more
europepmc   +1 more source

Engineered Bacteria Factory Integrating Drug Delivery and Antibody Manufacture for Activating the STING Signal Pathway Mediated Tumor Immunotherapy

Advanced Science, EarlyView.
To address the limitations of protein‐based ICIs in applications, this study constructed an engineered bacterium, HRB, capable of expressing aCD47 in hypoxic TME. Through the Schiff base reaction, responsive liposomes (LC) loaded with the STING agonist cGAMP were connected to the surface of bacteria to form HRB@LC.
Peng‐Shuo Dong, Tian Yao, Yong Li, Zi‐Hui Yan, Xiao‐Ting Xie, Jia‐Hua Zou, Kai Cheng, Jin‐Xuan Fan, Yuan‐Di Zhao, Qiu‐Ran Xu   +9 more
wiley   +1 more source

Emerging immune checkpoint targets and combination strategies in blood cancer immunotherapy. [PDF]

Ann Hematol
Al-Khreisat MJ, Abdulsahib WK, Jasim IK, Malathi H, Patro PS, Anand DA, Mukherjee G, Sinha A, Buriyeva D.   +8 more
europepmc   +1 more source

A Radioresistant‐Tumor‐Targeted Nanoparticle for X‐Ray‐Controlled Nitric Oxide Release to Potentiate Radiotherapy

Advanced Science, EarlyView.
The PBTN targets GRP78 and, upon X‐ray irradiation, generates ONOO− to induce immunogenic cell death, thereby activating CD8+ T cells and establishing a systemic antitumor immune response. ABSTRACT Nitric oxide (NO) treated radioresistant tumors by relieving hypoxia and blocking DNA repair, but its nonselective toxicity has precluded therapeutic use ...
Wanze Zhang, Xiaoyan Yin, Ting Wang, Hongfu Zhao, Zhipeng Zhao, Jinbao Wang, Cheng Tao, Xuanchu Ge, Yanze Li, Linlin Liu, Fuxin Xue   +10 more
wiley   +1 more source

Efficacy and safety of immune checkpoint inhibitor in clear cell ovarian cancer (CCC): the real world data

Ji-Hyun Lee, Jung‐Yun Lee, Eun Ji Nam, Sang Wun Kim, Sunghoon Kim, Young Tae Kim, Yong Jae Lee   +6 more
openalex   +1 more source

The AUTACE That Degrades KRAS and Engages CD8+ T Cells for the Treatment of KRAS/TP53 Co‐Mutant Tumors

Advanced Science, EarlyView.
AUTACE is a bifunctional nanoplatform that integrates tumor targeting, immune engagement, and on‐demand KRAS degradation. It targets KRAS/TP53 co‐mutant tumors via TP53‐specific TCRs, elicits antitumor CD8+ T‐cell responses through surface anti‐CD3 antibodies, and uses low‐intensity focused ultrasound (LIFU) to trigger controlled release of the KRAS ...
Luo Li, Bolin Li, Yanan Hao, Bo Pang, Pan Li, Chunli Li, Yu Tang   +6 more
wiley   +1 more source